Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × Sugars × Clear all

Phase

Phase 2 26 Phase 3 7 Phase NA 6 Phase 4 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 Paclitaxel 6 Etoposide 6 Drug Therapy 6 Leucovorin 5 Granulocyte Colony-Stimulating Factor 5 Filgrastim 5 Doxorubicin 5 Sirolimus 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Oxaliplatin 4 Nivolumab 4 Melphalan 4 Immunoglobulin G 4 Gemcitabine 4 Fluorouracil 4 Docetaxel 4 Disulfides 4 Cytarabine 4 Cisplatin 4 Carboplatin 4 Capecitabine 4 Bevacizumab 4 pembrolizumab 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 auricularum 3 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡